Pich,
That's what I'm thinking. busing on the initial bounce (1.58 - 1.76) might have been the opportunity. Interesting how these trials can make or break these biotechs. Appreciate those sites you provided as this is another classic example of sticking to the technicals and rooting out the emotional aspect of what the company's trying to accomplish.
My latest study is Magnum Hunter Resources (MHR). Bought over $5 and have dollar-cost averaged down to $4.05 per share. Realizing there recent activities of selling additional shares ay $4.50 to support their $311 million expansion in ND, the interest rates were a little higher than I'd expect at 10% annually but the deal brings to their piece of the property there to 43% and a 125% increase in daily oil production. With oil down right now, it'll be interesting to see where this one heads from here.
Cheers,
SS1
News 
Market Data 
Discover 
